Embecta Corp
$ 8.85
-0.23%
10 Apr - close price
- Market Cap 524,096,000 USD
- Current Price $ 8.85
- High / Low $ 8.99 / 8.74
- Stock P/E 3.75
- Book Value -10.35
- EPS 2.36
- Next Earning Report 2026-05-08
- Dividend Per Share $0.60
- Dividend Yield 6.76 %
- Next Dividend Date -
- ROA 0.18 %
- ROE N/A %
- 52 Week High 15.13
- 52 Week Low 8.47
About
Embecta Corp (EMBC) is a leading global medical technology firm dedicated to advancing diabetes management through its cutting-edge insulin delivery solutions. As a spin-off from Becton, Dickinson and Company, Embecta leverages innovative technologies and a comprehensive product portfolio—including insulin pens and syringes—to enhance patient care and health outcomes. Committed to operational excellence and customer-centric strategies, the company is strategically positioned to capitalize on growth opportunities in the fast-evolving diabetes care market. With a focus on improving patient experiences, Embecta aims to drive sustainable development and solidify its leadership in the industry.
Analyst Target Price
$16.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-25 | 2025-08-08 | 2025-05-07 | 2025-02-07 | 2024-11-19 | 2024-08-09 | 2024-05-09 | 2024-02-09 | 2023-11-21 | 2023-08-08 | 2023-05-12 |
| Reported EPS | 0.71 | 0.5 | 0.78 | 0.7 | 0.65 | 0.45 | 0.74 | 0.67 | 0.61 | 0.59 | 0.26 | 0.24 |
| Estimated EPS | 0.67 | 0.46 | 0.77 | 0.5875 | 0.4425 | 0.36 | 0.46 | 0.4 | 0.46 | 0.4 | 0.46 | 0.49 |
| Surprise | 0.04 | 0.04 | 0.01 | 0.1125 | 0.2075 | 0.09 | 0.28 | 0.27 | 0.15 | 0.19 | -0.2 | -0.25 |
| Surprise Percentage | 5.9701% | 8.6957% | 1.2987% | 19.1489% | 46.8927% | 25% | 60.8696% | 67.5% | 32.6087% | 47.5% | -43.4783% | -51.0204% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.42 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-17 | 2025-12-18 | 2025-09-15 | 2025-06-13 | 2025-03-14 | 2024-12-18 | 2024-09-13 | 2024-06-14 | 2024-03-15 | 2023-12-15 |
| Amount | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EMBC
2026-04-09 11:39:39
Embecta Corp is a leader in diabetes care devices, specializing in self-injection systems like its OnePouch line of syringes. Spun off from BD in 2022, the company benefits from a growing market with over 500 million people affected by diabetes worldwide, a number projected to reach 700 million by 2045. Investors should consider Embecta's stable cash flow, focus on organic growth, and position in a recession-resistant healthcare sector, while also monitoring risks such as reimbursement pressures and competition.
2026-04-08 15:38:59
embecta Corp. has announced new leadership appointments to its Board of Directors. Devdatt Kurdikar, the company's president and CEO, has been elected as the new chairman, succeeding David F. Melcher. Dr. Claire Pomeroy will serve as the lead independent director and continue her roles on key committees.
2026-04-04 21:48:00
This article provides an AI-generated analysis of Embecta Corp. (NASDAQ: EMBC), indicating a neutral sentiment across all time horizons with no clear price positioning signal. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and notes elevated downside risk due to a lack of long-term support signals.
2026-04-02 22:10:39
Embecta Corp (ISIN: US29082K1051) is an independent global leader in insulin delivery devices, focusing on self-injection systems for diabetes patients. Spun off from BD in 2022, the company leverages its OneTouch pen needle platform and other established brands to serve a market driven by rising global diabetes prevalence. Key growth drivers include product innovation, market penetration in emerging regions, and strategic independence, while facing competition from both large and specialized medical device companies.
2026-04-02 09:16:52
SG Americas Securities LLC acquired 435,842 shares of Embecta Corp. (NASDAQ:EMBC) in Q4, valued at approximately $5.18 million, representing about 0.74% of the company. Institutional investors now own 93.83% of Embecta, which pays a quarterly dividend of $0.15 (6.8% yield) and trades near $8.79. Despite beating Q4 estimates and setting FY2026 guidance, analysts maintain a consensus "Hold" rating with an average target price of $18.50.
2026-04-02 04:10:52
Embecta Corp, spun off from BD in 2022, is a specialized medical device company focused on self-injection systems, particularly for diabetes patients, with its flagship OneTouch pen needle platform. The company's business model emphasizes lean manufacturing, supply chain efficiency, and growth in emerging markets, leveraging established brands and consistent cash flow from recurring consumable sales. Key considerations for investors include its ability to innovate against competition, manage supply chain vulnerabilities, and navigate regulatory changes, while benefiting from increasing global diabetes prevalence.
